AC
CRVS icon

AXQ Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

AXQ Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Buy
13,732
+1,131
+9% +$18K 0.03% 748
2025
Q4 		$97K Sell
12,601
-14,450
-53% -$114K 0.02% 655
2025
Q3 		$199K Buy
+27,051
New +$138K 0.08% 454

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AXQ Capital's CRVS Position: Q1 2026 in Review

AXQ Capital increased its Corvus Pharmaceuticals (CRVS) stake by 9% in Q1 2026, buying an estimated $18K and bringing the position to 13,732 shares worth $201K. The position accounts for 0.03% of the portfolio, ranked #748.

AXQ Capital first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • AXQ Capital held 13,732 shares of Corvus Pharmaceuticals worth $201K as of Q1 2026.
  • AXQ Capital bought 1,131 Corvus Pharmaceuticals shares in Q1 2026, an estimated $18K.
  • Corvus Pharmaceuticals made up 0.03% of AXQ Capital's portfolio in Q1 2026, its #748 holding.
  • AXQ Capital first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.